- Home
- SBFM vs NIKI Comparison
SBFM vs NIKI Comparison
Compare SBFM & NIKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBFM | NIKI |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 3.8M |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SBFM | NIKI |
|---|---|---|
| Price | $0.17 | $1.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.1M | 15.1K |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,305,891.00 | N/A |
| Revenue This Year | $1.23 | N/A |
| Revenue Next Year | $22.44 | $48.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.11 | N/A |
| 52 Week Low | $0.19 | $1.83 |
| 52 Week High | $21.30 | $10.39 |
Technical Indicators
Market Signals| Indicator | SBFM | NIKI |
|---|---|---|
| Relative Strength Index (RSI) | 25.50 | 19.03 |
| Support Level | N/A | N/A |
| Resistance Level | $1.26 | $5.17 |
| Average True Range (ATR) | 0.13 | 0.39 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 0.81 | 1.27 |
Price Performance
Historical ComparisonAbout SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About NIKI Niki BioSolutions Inc. Common Stock
Niki BioSolutions Inc, formerly Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA).